使用FDA不良事件报告系统数据库在现实场景中评估 ivabradine 的安全概况
Fajun Li1, Xin Su2, Fuliang Cai1
1Department of Critical Care Medicine, The First People's Hospital of Kunshan, Kunshan, China.
Expert opinion on drug safety
|October 2, 2024
概括
这项研究分析了FDA对伊瓦布拉丁的不良事件报告,确定了26种药物诱导的不良事件,其中一些未列出. 女性患者出现某些副作用的风险更高,这表明 ivabradine 的使用更安全.
科学领域:
- 药物监督 药物监督 药物监督
- 心脏病学 心脏病学
- 药品安全 药品安全
背景情况:
- 伊瓦布拉丁适用于心力衰竭患者,心率升高.
- 关于伊瓦布拉丁的不良反应的现实世界数据有限.
- 了解药物安全性对于有效的患者护理至关重要.
研究的目的:
- 通过使用现实世界的数据来评估伊瓦布拉丁的不良事件概况.
- 识别潜在的安全问题和未列出的不良反应.
- 为优化 ivabradine 治疗提供证据.
主要方法:
- 从FDA的不良事件报告系统 (FAERS) 中分析不良事件报告.
- 利用顺序分析策略来评估不良事件的意义.
- 研究了不良事件的时间和性别特异性模式.
主要成果:
- 确定了2,701份与伊瓦布拉丁相关的不良事件报告.
- 检测到26个重要的伊瓦布拉丁诱导的不良事件,包括未列出的那些.
- 观察到女性的不良事件发生率较高,并且在治疗的第一个月内出现.
结论:
- 该研究确定了与 ivabradine 使用相关的关键不良事件.
- 调查结果突出了潜在的安全信号和性别特异性风险.
- 为临床医生提供宝贵的见解,以提高伊瓦布拉丁的疗效和安全性.
相关概念视频
Pharmacovigilance
784
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
784
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
716
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
716
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
921
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
921
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
789
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
789


